23809-57-6

Basic information

• Product Name: 5,5,5-TRIFLUORONORVALINE
• Synonyms: 5,5,5-TRIFLUORONORVALINE;5,5,5-Trifluoronorvaline 96%;5,5,5-Trifluoronorvaline96%;2-Amino-5,5,5-trifluoropentanoic acid 96%
• CAS NO: 23809-57-6
• Molecular Formula: C5H8F3NO2
• Molecular Weight: 171.12
• Mol File: 23809-57-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 256-258°C
• Boiling Point: 206.7°C at 760 mmHg
• Flash Point: 78.8°C
• Appearance: /
• Density: 1.356g/cm³
• Vapor Pressure: 0.0947mmHg at 25°C
• Refractive Index: 1.402
• PKA: pK1:2.042(+1);pK2:8.916(0) (25°C)
• CAS DataBase Reference: 5,5,5-TRIFLUORONORVALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,5,5-TRIFLUORONORVALINE(23809-57-6)
• EPA Substance Registry System: 5,5,5-TRIFLUORONORVALINE(23809-57-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 23809-57-6(Hazardous Substances Data)

Usage

General Description

5,5,5-Trifluoronorvaline, also known as trifluorovaline, is a fluorinated amino acid derivative with the chemical formula C5H9F3NO2. It is a non-proteinogenic amino acid that contains a trifluoromethyl group, making it useful in the field of medicinal chemistry and drug development. 5,5,5-TRIFLUORONORVALINE has been used as a building block in the synthesis of various pharmaceuticals and has shown potential in the development of novel peptide-based drugs. Its unique fluorinated structure offers enhanced stability and bioavailability, making it a valuable tool in the search for new therapeutic agents. Additionally, trifluorovaline has been studied for its potential as a molecular probe in the investigation of protein-protein interactions and cellular signaling pathways.

InChI:InChI=1/C5H8F3NO2/c6-5(7,8)2-1-3(9)4(10)11/h3H,1-2,9H2,(H,10,11)/t3-/m0/s1

Upstream product

• 23809-63-4 5-(3,3,3-trifluoropropyl)imidazolidine-2,4-dione 
• 96563-56-3 N-acetyl-5,5,5-trifluoronorvaline 
• 118311-19-6 5,5,5-Trifluoro-2-[(Z)-hydroxyimino]-pentanoic acid 
• 120097-66-7 diethyl α-(N-acetylamino)-α-(3,3,3-trifluoropropyl)malonate 
• 406-87-1 4,4,4-trifluorobutanal 
• 143-33-9 sodium cyanide 
• 118311-18-5 5,5,5-trifluoro-2-oxopentanoic acid 
• 118325-20-5 5,5,5-Trifluoro-2-oxo-pentanoic acid tert-butylamide 
• 1859-47-8 2-(benzylamino)-5,5,5-trifluoropentanoic acid 
• 453556-65-5 (S)-2-((tert-butoxycarbonyl)amino)-5,5,5-trifluoropentanoic acid 
• 1010423-89-8 N-benzyl-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-4,4,4-trifluorobut-2-yn-1-amine 
• 1010423-91-2 tert-butyl (R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-4,4,4-trifluorobutylcarbamate 
• 1010423-93-4 tert-butyl (2S,3S)-6,6,6-trifluoro-1,2-dihydroxyhexan-3-ylcarbamate 
• 2365-80-2 2-amino-5,5,5-trifluoropentanoic acid 

Downstream Products

• 1859-47-8 2-(benzylamino)-5,5,5-trifluoropentanoic acid 
• 122565-28-0 (S)-2-amino-5,5,5-trifluoropentanoic acid 
• 122565-29-1 (2R)-2-amino-5,5,5-trifluoropentanoic acid 
• 1392848-78-0 C₁₁H₁₀Cl₂F₃NO₃S 
• 1146699-67-3 (R)-2-(4-chlorophenylsulfonamido)-5,5,5-trifluoropentanamide 
• 1392848-77-9 (R)-2-(4-chlorophenylsulfonamido)-5,5,5-trifluoropentanoic acid 
• 1584149-67-6 (2R,3R)-N-((3S)-1-(3-cyanophenyl)-6-(difluoromethyl)-4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-phenyl-2-(3,3,3-trifluoropropyl)succinamide 
• 1584150-54-8 (2R,3R)-tert-butyl 3-(((S)-1-(3-cyanophenyl)-6-(difluoromethyl)-4-oxo-2,3,4,5-tetrahydro-1H-benzo-[b][1,4]-diazepin-3-yl)carbamoyl)-6,6,6-trifluoro-2-phenylhexanoate 
• 1584150-55-9 (2R,3R)-3-(((S)-1-(3-cyanophenyl)-6-(difluoromethyl)-4-oxo-2,3,4,5-tetrahydro-1H-benzo-[b][1,4]-diazepin-3-yl)carbamoyl)-6,6,6-trifluoro-2-phenylhexanoic acid 
• 1581734-83-9 (R)-2-((R)-2-(tert-butoxy)-2-oxo-1-phenylethyl)-5,5,5-trifluoropentanoic acid 
• 1581734-80-6 benzyl (2R)-5,5,5-trifluoro-2-hydroxypentanoate 
• 1581734-81-7 benzyl (2R)-5,5,5-trifluoro-2-{[(trifluoromethyl)sulfonyl]oxy}pentanoate 
• 1581734-82-8 (2R,3R)-1-benzyl 4-tert-butyl 3-phenyl-2-(3,3,3-trifluoropropyl)succinate 
• 1582185-20-3 C₃₃H₃₃F₅N₄O₆ 

Relevant articles and documents

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Chemical deracemization and (S) to (R) interconversion of some fluorine-containing α-amino acids

Several ω-CF3-substituted a-amino acids have been prepared in optically pure form via two complementary approaches. Racemic fluorinated derivatives of 2-aminobutanoic acid, norvaline and norleucine were chemically deracemized by complexation with a Ni(II) salt and a chiral reagent derived from α-(phenyl)ethylamine. Additionally this procedure also allowed the conversion of readily available L-amino acids, CF3-analogs of cysteine and methionine, into the corresponding unnatural D-series. Optically pure amino acids are obtained upon disassembly of the Ni(II) complexes with recovery of the chiral ligand.

NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION

The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, and/or dementia pugilistica and/or other conditions associated with β-amyloid peptide.